Compare iShares China Large-Cap ETF (FXI) vs HCA Health Inc (HCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs HCA Health Inc — how do they compare? iShares China Large-Cap ETF trades at $33.93 (market cap $3.90B), while HCA Health Inc trades at $443.69 (market cap $95.08B). The key difference: HCA Health Inc is far larger — about 24.4× iShares China Large-Cap ETF's market cap, and HCA Health Inc pays a 0.71% dividend while iShares China Large-Cap ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 149 Days and HCA Health Inc for 76 Days on average.
| FXI | HCA | |
|---|---|---|
Market Cap | $3.90B | $95.08B |
Volume | 16,526,479 | 998,787 |
52-Week High | $41.08 | $545.13 |
52-Week Low | $31.59 | $361.32 |
Typical Hold Time | 149 Days | 76 Days |
Sector | — | Health |
Enterprise Value | — | $145.62B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI (iShares China Large-Cap ETF) trades at $33.42, down 1.04% with a bearish technical outlook. The ETF shows compelling valuation at half the S&P 500's P/E ratio with a 1.98% yield, but faces headwinds from China's economic challenges and geopolitical tensions. Recent corporate profit growth of 26% in Q2 2026 provides fundamental support, though weak momentum persists amid global trade concerns.
The ETF offers diversification value and valuation appeal but carries significant political and economic risks. China's industrial overcapacity and weak domestic consumption create volatility, while U.S.-China relations remain a key variable. Institutional interest focuses on long-term value despite near-term bearish technical signals.
HCA Healthcare (HCA) trades at $445.01, up 2.96% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $75.6B in 2025, with net income of $6.78B, and the stock trades at a P/E of 14.73. Analyst consensus is a Buy with a $461.12 price target, though ongoing legal investigations pose a headwind.
The outlook remains positive given solid demand and cost controls, but risks include payer-mix pressure and high debt levels. Upside potential exists if earnings growth continues, but investors should monitor legal developments and interest rate impacts on the leveraged balance sheet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
